Serina Therapeutics, Inc. (SER): debt financing — AgeX Therapeutics draws $500,000 under secured convertible note due Feb 2024

Serina Therapeutics, Inc.

Drew $500,000 from credit available under Secured Note on July 5, 2023.
Outstanding principal balance due and payable on February 14, 2024.
Other material terms of the Secured Note previously filed in Form 10-Q and Form 8-K.

item 2.03 item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Serina Therapeutics, Inc. incurred convertible notes of $500,000 maturing February 14, 2024.

Instrument: convertible notes
Principal: $500,000
Maturity: February 14, 2024
Event: incurrence

Exact text from the filing

On July 5, 2023, AgeX drew $500,000 of its credit available under the Allonge and Restated Convertible Promissory Note (“Secured Note”) as amended on June 2, 2023.

View on SEC.gov

Browse all debt financings →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-023975

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.